Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis

References

• Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest. 2007;117(4):868–870.
   PubMed Web of Science ®Google Scholar
• Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347(jul29 3):f4533–f4533.
   PubMedGoogle Scholar
• McCoy RG, Van Houten HK, Ziegenfuss JY, et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35(9):1897–1901.
   PubMed Web of Science ®Google Scholar
• Heller SR, Frier BM, Hersløv ML, et al. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. Diabet Med. 2016;33(4):471–477.
   PubMed Web of Science ®Google Scholar
• Ratzki-Leewing A, Harris SB, Mequanint S, et al. Real-world crude incidence of hypoglycemia in adults with diabetes: results of the InHypo-DM study, Canada. BMJ Open Diabetes Res Care. 2018;6(1):e000503.
   PubMed Web of Science ®Google Scholar
• Aronson R, Goldenberg R, Boras D, et al. The canadian hypoglycemia assessment tool program: insights into rates and implications of hypoglycemia from an observational study. Can J Diabetes. 2018;42(1):11–17.
   PubMed Web of Science ®Google Scholar
• Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–1640.
   PubMed Web of Science ®Google Scholar
• Hermanns N, Heinemann L, Freckmann G, et al. Impact of CGM on the management of hypoglycemia problems: overview and secondary analysis of the HypoDE study. J Diabetes Sci Technol. 2019;13(4):636–644.
   PubMedGoogle Scholar
• Messaaoui A, Tenoutasse S, Crenier L. Flash glucose monitoring accepted in daily life of children and adolescents with type 1 diabetes and reduction of severe hypoglycemia in real-Life use. Diabetes Technol Ther. 2019;21(6):329–335.
   PubMed Web of Science ®Google Scholar
• International Hypoglycaemia Study Group. Minimizing hypoglycemia in diabetes. Diabetes Care. 2015;38(8):1583–1591.
   PubMed Web of Science ®Google Scholar
• Wild D, von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns. 2007;68(1):10–15.
   PubMed Web of Science ®Google Scholar
• Foos V, Varol N, Curtis BH, et al. Economic impact of severe and non-severe hypoglycemia in patients with type 1 and type 2 diabetes in the United States. J Med Econ. 2015;18(6):420–432.
   PubMed Web of Science ®Google Scholar
• Meneghini LF, Lee LK, Gupta S, et al. Association of hypoglycaemia severity with clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin. Diabetes Obes Metab. 2018;20(5):1156–1165.
   PubMed Web of Science ®Google Scholar
• Mojdami D, Peyrot M, Spaepen E, et al. 115 – Conversations and reactions around severe hypoglycemia (CRASH study): Canadian results. Can J Diabetes. 2019;43(7):S40.
   PubMedGoogle Scholar
• Diabetes Canada Clinical Practice Guidelines Expert Committee; Yale JF, Paty B, Senior PA. 2018 Clinical practice guidelines hypoglycemia. Can J Diabetes. 2018;42(Supplement 1):S104–S108.
   PubMedGoogle Scholar
• Eli Lilly Canada Inc. GLUCACON (rDNA Origin) Product Monograph [cited 2020 Apr 3]. Available from: https://www.lilly.ca/en/pdf/consumer-information/04_rglucagon-ci_9july2012.pdf
   Google Scholar
• Harris G, Diment A, Sulway M, et al. Glucagon administration – underevaluated and undertaught. Pract Diab Int. 2001;18(1):22–25.
   Google Scholar
• Pontiroli AE. Intranasal glucagon: a promising approach for treatment of severe hypoglycemia. J Diabetes Sci Technol. 2015;9(1):38–43.
   PubMedGoogle Scholar
• Eli Lilly Canada Inc. BAQSIMI™ glucagon nasal powder Product Monograph [cited 2020 Apr 3]. http://pi.lilly.com/ca/baqsimi-ca-pm.pdf
   Google Scholar
• Sherr JL, Ruedy KJ, Foster NC, et al. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care. 2016;39(4):555–562. ;.
   PubMed Web of Science ®Google Scholar
• Pack BW, Melnick JP, Breen CC, et al. (IP11) Portability of nasal glucagon for the rescue of severe hypoglycemia: Stability and performance when exposed to temperature extremes. Association of Diabetes Care & Education Specialists. 2021 Annual Conference; Virtual; August 12–15; 2021.
   Google Scholar
• Rickels MR, Ruedy KJ, Foster NC, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care. 2016;39(2):264–270.
   PubMed Web of Science ®Google Scholar
• Yale JF, Dulude H, Egeth M, et al. Faster use and fewer failures with needle-free nasal glucagon versus injectable glucagon in severe hypoglycemia rescue: a simulation study. Diabetes Technol Ther. 2017;19(7):423–432.
   PubMed Web of Science ®Google Scholar
• Settles J, Child CJ, Bajpai SK, et al. 13-LB: nasal vs. injected glucagon: user experience results of a simulated severe hypoglycemia study. Diabetes. 2019;68(Supplement 1):13-LB.
   Google Scholar
• Seaquist ER, Dulude H, Zhang XM, et al. Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting. Diabetes Obes Metab. 2018;20(5):1316–1320.
   PubMed Web of Science ®Google Scholar
• Deeb LC, Dulude H, Guzman CB, et al. A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting. Pediatr Diabetes. 2018;19(5):1007–1013.
   PubMed Web of Science ®Google Scholar
• Sinclair JE, Austin M, Froats M, et al. Characteristics, prehospital management, and outcomes in patients assessed for hypoglycemia: repeat access to prehospital or emergency care. Prehosp Emerg Care. 2019;23(3):364–376.
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Families, households and marital status: key results from the 2016 Census [cited 2019 Jun 4]. Available from: https://www150.statcan.gc.ca/n1/daily-quotidien/170802/dq170802a-eng.htm
   Google Scholar
• Rowe BH, Singh M, Villa-Roel C, et al. Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia. Can J Diabetes. 2015;39:9–18.
   PubMed Web of Science ®Google Scholar
• Ontario Drug Benefit Formulary/Comparative Drug Index [cited 2019 Jun 4]. Available from: https://www.formulary.health.gov.on.ca/formulary/results.xhtml?q=glucagon&type=1
   Google Scholar
• Toronto Paramedic Service. Annual report 2017 [cited 2019 Jun 4]. Available from: https://www.toronto.ca/wp-content/uploads/2018/03/9730-Toronto-Paramedic-Services-Annual-Report-2017-sm.pdf
   Google Scholar
• Government of Ontario. Ontario Case Costing Initiative (OCCI) [cited 2019 Jun 4]. Available from: https://www.ontario.ca/data/ontario-case-costing-initiative-occi
   Google Scholar
• Alexiu CJ, Chuck A, Jelinski SE, et al. Presentations for hypoglycemia associated with diabetes mellitus to emergency departments in a Canadian province: a database and epidemiological analysis. Diabetes Res Clin Pract. 2017;130:229–236.
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Labour force survey estimates (LFS), wages of employees by type of work, National Occupational Classification for Statistics (NOC-S), sex and age group, unadjusted for seasonality [cited 2019 Jun 4]. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1410006101&pickMembers%5B0%5D=1.1&pickMembers%5B1%5D=2.2&pickMembers%5B2%5D=3.1&pickMembers%5B3%5D=5.1&pickMembers%5B4%5D=6.1
   Google Scholar
• Ministry of Health and Long Term Care. Schedule of benefits [cited 2021 Jun 28]. Available from: http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master20181115.pdf
   Google Scholar
• Ontario Drug Benefit Formulary/Comparative Drug Index [cited 2019 Jun 4]. Available from: https://www.formulary.health.gov.on.ca/formulary/results.xhtml?q=glucose%2Bstrip&type=2
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidance document for the costing of health care resources in the Canadian setting. 2nd ed. [cited 2019 Jun 4]. Available from: https://www.cadth.ca/guidance-document-costing-process-2e
   Google Scholar
• Daneman D, Frank M, Perlman K, et al. Severe hypoglycemia in children with insulin-dependent diabetes mellitus: frequency and predisposing factors. J Pediatr. 1989;115(5 Pt 1):681–685.
   PubMed Web of Science ®Google Scholar
• Spaic T, Peddle M, Mahon J, et al. Emergency medical services (EMS) assist-requiring hypoglycemia in diabetes patients. Can J Diabetes. 2016;40(5):S12.
   PubMedGoogle Scholar
• Alberta Health Services. Quarterly Emergency Medical Services Dashboard [cited 2019 Jun 4]. Available from: https://www.albertahealthservices.ca/assets/about/ems/ahs-ems-dashboard.pdf
   Google Scholar
• Food and Drug Administration. ZEGALOGUE (dasiglucagon) injection, for subcutaneous use: Prescribing information [cited 2022 Jan 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000lbl.pdf
   Google Scholar
• Food and Drug Administration. GVOKE (glucagon) injection, for subcutaneous use: prescribing information [cited 2022 Jan 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212097Orig1s000lbl.pdf
   Google Scholar
• Pöhlmann J, Mitchell BD, Bajpai S, et al. Nasal glucagon versus injectable glucagon for severe hypoglycemia: a cost-offset and budget impact analysis. J Diabetes Sci Technol. 2019;13(5):910–918.
   PubMedGoogle Scholar
• Harris S, Mamdani M, Galbo-Jørgensen CB, et al. The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey. Can J Diabetes. 2014;38(1):45–52.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523–1534.
   PubMed Web of Science ®Google Scholar
• Davis RE, Morrissey M, Peters JR, et al. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin. 2005;21(9):1477–1483.
   PubMed Web of Science ®Google Scholar
• Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11:90.
   PubMed Web of Science ®Google Scholar